Would you consider adjuvant TDM-1 for a patient with HR+,HER2+ breast cancer with pCR in the breast but N1mic disease post neoaduvant chemotherapy?
N1mic - few isolated malignant cells in 1 axillary lymph node
Answer from: Medical Oncologist at Academic Institution
The Katherine Trial (NEJM 2019:380;617-280) was a randomized trial of trastuzumab emtansine (TDM-1) versus trastuzumab for patients with residual disease after HER2-directed neoadjuvant treatment. The trial was positive for TDM-1. The randomized patients included those with residual invasive disease...
Sign in or Register to read more